OCUGEN INC. - COMMON

Ocugen Provides Business Update with First Quarter 2023 Financial Results

05 May 2023 06:00:30 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results

28 Apr 2023 06:00:40 By Nasdaq GlobeNewswire

Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies

27 Apr 2023 06:25:53 By Nasdaq GlobeNewswire

Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference

26 Apr 2023 05:30:53 By Nasdaq GlobeNewswire

Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting

20 Apr 2023 07:00:45 By Nasdaq GlobeNewswire

Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

14 Apr 2023 06:45:16 By Nasdaq GlobeNewswire

Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023

11 Apr 2023 17:20:58 By Nasdaq GlobeNewswire

Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress

31 Mar 2023 07:15:00 By Nasdaq GlobeNewswire

Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

27 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference

07 Mar 2023 07:00:24 By Nasdaq GlobeNewswire

Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer

06 Mar 2023 06:02:09 By Nasdaq GlobeNewswire

Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results

28 Feb 2023 06:00:25 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema

27 Feb 2023 16:57:17 By Nasdaq GlobeNewswire

Ocugen to Present at Retinal Vascular Disease Drug Development Summit

17 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results

15 Feb 2023 15:30:00 By Nasdaq GlobeNewswire

Ocugen Appoints Quan A. Vu as Chief Business Officer

01 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference

31 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met

09 Jan 2023 05:00:00 By Nasdaq GlobeNewswire

Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®

16 Dec 2022 05:30:56 By Nasdaq GlobeNewswire

Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis

15 Dec 2022 16:15:49 By Nasdaq GlobeNewswire